Item 7.01. Regulation FD.

On January 4, 2023, Reviva Pharmaceutical Holdings, Inc. (the "Company") issued a press release containing a letter addressed to the Company's shareholders from the Company's President and Chief Executive Officer, Laxminarayan Bhat, Ph.D. A copy of the letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.   Description

99.1            Press Release, dated January 4, 2023.

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses